Atea Pharmaceuticals, Inc. AVIR
4.28 USD +0.08 (+1.89%)
Nov 11, 2026, 1:06 PM EST
4.04 Day range 4.34
2.87 52-week range 6.45
- YTD
- +19.87%
- 1 year
- +26.61%
News
seekingalpha.com Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript Atea Pharmaceuticals, Inc. (AVIR) Q3 2026 Earnings Call Transcript
marketbeat.com What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call Atea Pharmaceuticals NASDAQ: AVIR is targeting a mid-2027 U.S. application for its hepatitis C treatment, pending results from a second late-stage trial, and has secured a credit facility of up to…
benzinga.com CORRECTION: Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0.42) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 4.76 percent. This is a 24.53 percent increase over losses of…
benzinga.com Atea Pharmaceuticals Q3 2026 Earnings Call Transcript Atea Pharmaceuticals (NASDAQ:AVIR) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Atea Pharmaceuticals Q3 EPS $0.40 Beats $(0.42) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $(0.42) by 195.24 percent. This is a 175.47 percent increase over losses…
globenewswire.com Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection
globenewswire.com Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral…
benzinga.com Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7 Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
benzinga.com Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.- benzinga.com Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL (Epclusa) at Week 24, encompassing SVR at 12 weeks…
- benzinga.com Atea Pharmaceuticals Initiates First-in-human Phase 1 Clinical Trial Of AT-587 For Hepatitis E Virus Infection Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares…
benzinga.com Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus Infection Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North AmericaC-FORWARD and C-BEYOND Represent the…
benzinga.com Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - benzinga.com Atea Pharmaceuticals Q1 EPS $(0.57) Beats $(0.59) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.59) by 3.39 percent. This is a 42.5 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com Top 2 Health Care Stocks That May Fall Off A Cliff This Month Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX) and Atea Pharma (AVIR) among top-ranked.
benzinga.com Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10 Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.
benzinga.com Atea Pharmaceuticals Q4 EPS $(0.57) Misses $(0.53) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 42.5 percent decrease over losses…- benzinga.com Earnings Scheduled For March 5, 2026
benzinga.com Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings - benzinga.com Atea Pharmaceuticals Completes Enrollment Of Over 880 Treatment-naïve Patients In C-BEYOND Phase 3 Trial Of Fixed-dose Combination Bemnifosbuvir And Ruzasvir Compared To Sofosbuvir And Velpatasvir Regime For Hepatitis C Virus; Results Are Expected Mid-year 2026 In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWARD, a Phase 3 trial evaluating this same FDC regimen in 880 patients at approximately 120 clinical…
benzinga.com Atea Pharmaceuticals Q3 EPS $(0.53) Misses $(0.44) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.44) by 20.45 percent. This is a 43.24 percent decrease over losses…- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com Atea Pharmaceuticals Earnings Preview - benzinga.com Atea Pharmaceuticals Released New Modeling Data Showing Its Bemnifosbuvir And Ruzasvir Combination Regimen Achieved Near-Complete Inhibition Of HCV Replication And Secretion, With A Predicted Cure Time Of 7–8 Weeks Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
- benzinga.com Atea Pharma To Present New Data Supporting Combination Regimen Of Bemnifosbuvir As Potential For HCV Infection Treatment At The Liver Meeting 2025, AASLD Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
- benzinga.com Atea Pharmaceuticals Q2 EPS $(0.44) Misses $(0.43) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 8.33 percent increase over losses…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Atea Begins Global Late-Stage Trial of Oral Hepatitis C Drug Combo Aimed at Easier, Faster Cure Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral…
- benzinga.com Atea Pharmaceuticals Q1 EPS $(0.40) Beats $(0.41) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 46.67 percent increase over losses of…
benzinga.com Atea Pharmaceuticals Releases Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus, Including Confirmed 98% Sustained Virologic Response At 12 Weeks Post-Treatment After Short 8-Week Treatment Duration For Regimen Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for RegimenResults from Phase 1 Study Showed Low…- benzinga.com Atea Pharma Presents Results From Full Cohort Of Patients Enrolled In Phase 2 Study Evaluating Once-daily Combination Of BEM And RZR For Treatment Of Hepatitis C Virus Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for RegimenResults from Phase 1 Study Showed Low…
- benzinga.com Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6 Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and lowers the price target from $6.2 to $6.
benzinga.com Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.- benzinga.com Atea Pharmaceuticals Q4 EPS $(0.40) Misses $(0.37) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 14.89 percent increase over losses…
- benzinga.com Earnings Scheduled For March 6, 2025
- benzinga.com Atea Pharmaceuticals Reports Its Cash, Cash Equivalents And Marketable Securities Balance Of $454.7M At December 31, 2024 And A Cash Runway Anticipated Into 2028 Global Phase 3 HCV Program Expected to Initiate in 1Q 2025Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of…
- benzinga.com After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir.
benzinga.com Atea Pharmaceuticals Q3 2024 GAAP EPS $(0.37) Beats $(0.49) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.49) by 24.49 percent. This is a 7.5 percent increase over losses of…
benzinga.com Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.- benzinga.com Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- benzinga.com Atea Pharmaceuticals Updates On Global Phase 3 SUNRISE-3 Trial On Bemnifosbuvir For Treatment Of COVID-19; Says Trial Did Not Meet Primary Endpoint The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with…
- benzinga.com Atea Pharmaceuticals Announced Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today…
- benzinga.com Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88 Morgan Stanley analyst Matthew Harrison upgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and raises the price target from $2 to $6.88.
- benzinga.com Atea Pharmaceuticals Q2 2024 GAAP EPS $(0.48) Beats $(0.77) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.77) by 37.66 percent.
- benzinga.com Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk.
- benzinga.com Atea Pharmaceuticals Presents Initail Phase 2 Results for Bemnifosbuvir And Ruzasvir Mix In Treating Hepatitis C At The 2024 EASL Congress 97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High…
- benzinga.com Atea Pharmaceuticals Q1 2024 GAAP EPS $(0.75) Misses $(0.61) Estimate Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 74.42 percent decrease over losses…
- benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.